Objectives Board of Directors Advisory Board Leadership Sponsors
CIB2012 CIB2011 CIB2010 ICTM 2011
Executive Committee Education Committee International Collaboration Committee Communication Committee Membership Committee
Cellular & Molecular Medicine Applied Immunology Molecular Imaging Regenerative medicine Drug development and discovery Biomaterials & Clinical Application Omics Science
ISTM Newsletter Journals
Certification and Diplomate Program Short Term Training Abroad Long Term Abroad Training Fellowship Observer-ships Abroad
Conferences Travel Grants Travel Grants for Short Term Training Abroad Travel Fellowship for Long Term Abroad Training Observer-ships Abroad Grants Excellent in Translational Medicine Award Research Grants
News Home>>News

Prof Wang defines the concept of clinical trans-omics

 Clinical trans-omics is a new emerging scientific discipline that integrates clinical phenomes with molecular multiomics, in order to further understand molecular mechanisms of disease pathogenesis and progression, patient sensitivity to therapy and prognosis, and therapy design and development. The importance of clinical trans-omics lies in its possible production of a new and novel therapeutic strategy for diseases which can be designed based on altered omics profiles, improve the understanding of patient signs and symptoms in multiple dimensions, and lead us into the era of molecular medications. The most critical and challenging factor in the application of clinical trans-omics is to have automatic learning systems, which can dynamically generate, collect, integrate, and analyze large-scale data of multiomics. A large number of challenges, however, still need to be overcome. The “trans” is a key word that indicates the gathering and/or spanning of various layers of omics in different forms, which may sometimes be completely incomparable to each other. For example, the expression of genomic and proteomic profiles can be presented as the density or rationales a digital values, while most of the clinical phenotypes are recorded as word-descriptive or image-based information. There is increasing evidence to show the potential of this approach as more tools and methodologies are discovered and developed to build up the correlation and network of molecular multiomics with clinical phenotypes, identify disease-specific individual phenomes by patient trait prediction using whole-genome sequencing data, and indicate genetic alterations by gene profiling prediction using patient phenomics. The current application of clinical trans-omics is focused on the discovery and development of disease-specific diagnostic biomarkers and therapeutic targets. Clinical trans-omics will furthermore be applied for the design and decision-making regarding therapeutic strategies for individuals and for the prediction of patient prognosis and burden of social medical care. It is time to define and translate the concept of clinical trans-omics into clinical practice to benefit patients, especially those with serious, rare, or complex diseases.

Sponsors

Copyright © 2011 istmed.org All rights Reserved.  International Society for Translational Medicine

Technical support: weicheng